Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Rural Communities Should Benefit From Budget Health Boost
The Royal Australian College of General Practitioners (RACGP) National Rural Faculty has welcomed the increased funding for some existing programs and funding for new programs announced in this week"s federal budget. These increases in funding are welcome given the difficult economic climate in which this budget has been delivered.
generic viagra online
What Are Fibroids? What Are The Treatments For Fibroids?
Fibroids are non-cancerous (benign) tumors that grow from the muscle layers of the uterus (womb). They are also known as uterine fibroids, myomas, or fibromyomas. The singular of uterine fibroids is Uterine Fibroma. Fibroids are growths of smooth muscle and fibrous tissue. Fibroids can vary in size, from that of a bean to as large as a melon.
News of the day
What Is Embolism? What Are The Different Types Of Embolism?
An embolism - from the Greek çİmbolos meaning "stopper" or "plug" - is the term that describes a condition where an object called an embolus is created in one part of the body, circulates throughout the body, and then blocks blood flowing through a vessel in another part of the body. Emboli (plural of embolus) are not to be confused with thrombi (plural of thrombus), which are clots that are formed and remain in one area of the body without being carried throughout the bloodstream.
Health Insurance

Inconclusive Research Links Glargine Insulin (Lantus) With Cancer

Diabetes UK has today cautioned that research claiming there is a link between certain insulins and some cancers is "inconclusive". Results of four studies looking at the risk of cancer largely in people with Type 2 diabetes treated with insulin, particularly glargine insulin (Lantus), were published in Diabetologia - the Journal of the European Association for the Study of Diabetes - last week. The studies were based in Germany, Sweden, Scotland and the UK. The data of around 300,000 people treated with insulin was reviewed in the studies, of which 34,392 were taking glargine insulin (Lantus) alone. The German study suggested there may be a small increased risk of cancer in those taking glargine as their only insulin; with the strongest link seeming to be with breast cancer in older people. This small increase in risk appeared in two of the other three studies and seemed to be more so in people on high doses. Sir Professor George Alberti, Chairman of Diabetes UK, said: "It should be stated firmly that the evidence in these studies is not conclusive and that there are limitations with the research. "People with diabetes who are using glargine insulin should continue to take their medication as prescribed. You will become very ill if you stop taking your insulin. If you are concerned about these findings then you should speak to your healthcare team about your anxieties before discontinuing any treatment." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009